<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38969238</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2742</ISSN><JournalIssue CitedMedium="Internet"><Volume>89</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Journal of infection</Title><ISOAbbreviation>J Infect</ISOAbbreviation></Journal><ArticleTitle>Short- and long-term effects of imatinib in hospitalized COVID-19 patients: A randomized trial.</ArticleTitle><Pagination><StartPage>106217</StartPage><MedlinePgn>106217</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jinf.2024.106217</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0163-4453(24)00151-8</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">We studied the short- and long-term effects of imatinib in hospitalized COVID-19 patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Participants were randomized to receive standard of care (SoC) or SoC with imatinib. Imatinib dosage was 400&#xa0;mg daily until discharge (max 14 days). Primary outcomes were mortality at 30 days and 1 year. Secondary outcomes included recovery, quality of life and long COVID symptoms at 1 year. We also performed a systematic review and meta-analysis of randomized trials studying imatinib for 30-day mortality in hospitalized COVID-19 patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We randomized 156 patients (73 in SoC and 83 in imatinib). Among patients on imatinib, 7.2% had died at 30 days and 13.3% at 1 year, and in SoC, 4.1% and 8.2% (adjusted HR 1.35, 95% CI 0.47-3.90). At 1 year, self-reported recovery occurred in 79.0% in imatinib and in 88.5% in SoC (RR 0.91, 0.78-1.06). We found no convincing difference in quality of life or symptoms. Fatigue (24%) and sleep issues (20%) frequently bothered patients at one year. In the meta-analysis, imatinib was associated with a mortality risk ratio of 0.73 (0.32-1.63; low certainty evidence).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The evidence raises doubts regarding benefit of imatinib in reducing mortality, improving recovery and preventing long COVID symptoms in hospitalized COVID-19 patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Halme</LastName><ForeName>Alex L E</ForeName><Initials>ALE</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Helsinki, Helsinki, Finland. Electronic address: alex.halme@helsinki.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laakkonen</LastName><ForeName>Sanna</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Helsinki, Helsinki, Finland. Electronic address: sanna.laakkonen@helsinki.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rutanen</LastName><ForeName>Jarno</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Faculty of Social Sciences, Tampere University, Tampere, Finland; Department of Internal Medicine, Tampere University Hospital, Tampere, Finland. Electronic address: jarno.rutanen@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nevalainen</LastName><ForeName>Olli P O</ForeName><Initials>OPO</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Helsinki, Helsinki, Finland; Faculty of Social Sciences, Tampere University, Tampere, Finland; Hatanp&#xe4;&#xe4; Health Center, Wellbeing Services County of Pirkanmaa, Tampere, Finland. Electronic address: olli.neval@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sinisalo</LastName><ForeName>Marjatta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Tampere University Hospital, Tampere, Finland. Electronic address: sinisalo.um@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horstia</LastName><ForeName>Saana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Helsinki, Helsinki, Finland. Electronic address: saana.horstia@helsinki.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mustonen</LastName><ForeName>Jussi M J</ForeName><Initials>JMJ</Initials><AffiliationInfo><Affiliation>Mehil&#xe4;inen Oy, Helsinki, Finland. Electronic address: jussi.m.mustonen@mehilainen.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pourjamal</LastName><ForeName>Negar</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Helsinki, Helsinki, Finland. Electronic address: negar.pourjamal@helsinki.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanhanen</LastName><ForeName>Aija</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laakso Hospital, City of Helsinki, Helsinki, Finland. Electronic address: aija.vanhanen@hel.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Solidarity Finland Investigators</CollectiveName></Author><Author ValidYN="Y"><LastName>Rosberg</LastName><ForeName>Tuomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pulmonology, Kanta-H&#xe4;me Central Hospital, H&#xe4;meenlinna, Finland. Electronic address: tuomas.rosberg@omahame.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Renner</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland; Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Department of Pneumology, University Hospital Vienna, Medical University of Vienna, Vienna, Austria. Electronic address: andreas.renner@meduniwien.ac.at.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perola</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Public Health and Welfare, Population Health Unit, Public Health Research Team, Finnish Institute for Health and Welfare, Helsinki, Finland; Clinical and Molecular Metabolism Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland. Electronic address: markus.perola@thl.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paukkeri</LastName><ForeName>Erja-Leena</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Tampere University Hospital, Tampere, Finland. Electronic address: erja-leena.paukkeri@pirha.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patovirta</LastName><ForeName>Riitta-Liisa</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Department of Medicine, Kuopio University Hospital, Kuopio, Finland. Electronic address: riitta-liisa.patovirta@kuh.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parkkila</LastName><ForeName>Seppo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health Technology, Tampere University and Fimlab Ltd., Tampere University Hospital, Tampere, Finland. Electronic address: seppo.parkkila@tuni.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paajanen</LastName><ForeName>Juuso</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland; Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland. Electronic address: juuso.paajanen@hus.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nyk&#xe4;nen</LastName><ForeName>Taina</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Surgery, Hyvink&#xe4;&#xe4; Hospital, Hyvink&#xe4;&#xe4;, Finland. Electronic address: taina.nykanen@hus.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xe4;ntyl&#xe4;</LastName><ForeName>Jarkko</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland. Electronic address: jarkko.mantyla@hus.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Myll&#xe4;rniemi</LastName><ForeName>Marjukka</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland; Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland. Electronic address: marjukka.myllarniemi@hus.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mattila</LastName><ForeName>Tiina</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland. Electronic address: tiina.m.mattila@hus.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leinonen</LastName><ForeName>Maarit K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Teratology Information Service, Emergency Medicine and Services, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Electronic address: maarit.leinonen@hus.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xfc;lm&#xe4;su</LastName><ForeName>Alvar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, P&#xe4;ij&#xe4;t-H&#xe4;me Central Hospital, Lahti, Finland. Electronic address: alvar.kulmasu@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuutti</LastName><ForeName>Pauliina</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Helsinki, Helsinki, Finland. Electronic address: pauliina.kuutti@helsinki.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuitunen</LastName><ForeName>Ilari</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Mikkeli Central Hospital, Mikkeli, Finland; Institute of Clinical Medicine and Department of Pediatrics, University of Eastern Finland, Kuopio, Finland. Electronic address: ilari.kuitunen@uef.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kreivi</LastName><ForeName>Hanna-Riikka</ForeName><Initials>HR</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland. Electronic address: hanna-riikka.kreivi@hus.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kilpel&#xe4;inen</LastName><ForeName>Tuomas P</ForeName><Initials>TP</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Electronic address: tuomas.kilpelainen@hus.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kauma</LastName><ForeName>Heikki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Oulu University Hospital, Oulu, Finland. Electronic address: heikkikauma@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalliala</LastName><ForeName>Ilkka E J</ForeName><Initials>IEJ</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynaecology, Helsinki University and Helsinki University Hospital, Helsinki, Finland; Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK. Electronic address: ilkka.kalliala@hus.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>J&#xe4;rvinen</LastName><ForeName>Petrus</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Electronic address: petrus.jarvinen@hus.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hankkio</LastName><ForeName>Riina</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Tampere University Hospital Pharmacy, Tampere University Hospital, Tampere, Finland. Electronic address: riina.hankkio@pirha.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hammar&#xe9;n</LastName><ForeName>Taina</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laakso Hospital, City of Helsinki, Helsinki, Finland. Electronic address: taina.hammaren@hel.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feuth</LastName><ForeName>Thijs</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Diseases and Allergology, Division of Medicine, University of Turku and Turku University Hospital, Turku, Finland. Electronic address: matfeu@utu.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ansakorpi</LastName><ForeName>Hanna</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Research Unit of Clinical Neuroscience, Neurology, University of Oulu, Oulu, Finland. Electronic address: hanna.ansakorpi@oulu.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ala-Karvia</LastName><ForeName>Riikka</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Sein&#xe4;joki Central Hospital, Sein&#xe4;joki, Finland. Electronic address: riikka.ala-karvia@hyvaep.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guyatt</LastName><ForeName>Gordon H</ForeName><Initials>GH</Initials><AffiliationInfo><Affiliation>Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada; Department of Medicine, McMaster University, Hamilton, Ontario, Canada. Electronic address: guyatt@mcmaster.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tikkinen</LastName><ForeName>Kari A O</ForeName><Initials>KAO</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Helsinki, Helsinki, Finland; Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada; Department of Surgery, South Karelian Central Hospital, Lappeenranta, Finland. Electronic address: kari.tikkinen@helsinki.fi.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Infect</MedlineTA><NlmUniqueID>7908424</NlmUniqueID><ISSNLinking>0163-4453</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>8A1O1M485B</RegistryNumber><NameOfSubstance UI="D000068877">Imatinib Mesylate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068877" MajorTopicYN="Y">Imatinib Mesylate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Clinical Trials</Keyword><Keyword MajorTopicYN="N">Imatinib</Keyword><Keyword MajorTopicYN="N">Immunomodulatory effects</Keyword><Keyword MajorTopicYN="N">Long COVID patient outcomes</Keyword><Keyword MajorTopicYN="N">Post-COVID</Keyword><Keyword MajorTopicYN="N">Post-acute COVID syndrome</Keyword><Keyword MajorTopicYN="N">Randomized controlled trial</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 infection</Keyword><Keyword MajorTopicYN="N">Tyrosine kinase inhibitors</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Hanna-Riikka Kreivi is a consultant for Pfizer and Roche and received lecture honoraria from Pfizer. Tiina Mattila is an advisory board member for GSK and received lecture honoraria from AstraZeneca, Boehringer-Ingelheim, Chiesi, GSK, and Orion. All other authors declare no competing interests.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Ala-Kokko</LastName><ForeName>Tero</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Oulu University Hospital and University of Oulu, Oulu, Finland.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Gockel</LastName><ForeName>Maarit</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laakso Hospital, City of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Haapanen</LastName><ForeName>Susanna</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Tampere University Hospital, Tampere, Finland.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Haukip&#xe4;&#xe4;</LastName><ForeName>Mia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Infectious and Pulmonary Diseases, Hyvink&#xe4;&#xe4; Hospital, Hyvink&#xe4;&#xe4;, Finland.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Lehtonen</LastName><ForeName>Sanna</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Nieminen</LastName><ForeName>Eeva-Maija</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Niskanen</LastName><ForeName>Joni</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Tampere University Hospital, Tampere, Finland.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Oksi</LastName><ForeName>Jarmo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, University of Turku and Turku University Hospital, Turku, Finland.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Otava</LastName><ForeName>Ulla</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Tampere University Hospital, Tampere, Finland.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Rutanen</LastName><ForeName>Taija</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Suomen COVID-yhdistys ry, Finland.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Salmela</LastName><ForeName>Petri</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Tampere University Hospital, Tampere, Finland.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Savolainen</LastName><ForeName>Joni</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Suomen COVID-yhdistys ry, Finland.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Tuominen</LastName><ForeName>Susanna</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Vartiainen</LastName><ForeName>Henri</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, P&#xe4;ij&#xe4;t-H&#xe4;me Central Hospital, Lahti, Finland.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Yl&#xe4;-Outinen</LastName><ForeName>Heli</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Diseases and Allergology, Division of Medicine, University of Turku and Turku University Hospital, Turku, Finland.</Affiliation></AffiliationInfo></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>13</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>6</Day><Hour>10</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>5</Day><Hour>19</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38969238</ArticleId><ArticleId IdType="doi">10.1016/j.jinf.2024.106217</ArticleId><ArticleId IdType="pii">S0163-4453(24)00151-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>